| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Pediatric Endocrinology and Diabetes (S.L.F., P.C.), Mattel Childrens Hospital, University of California, Los Angeles, California 90095-1752; and Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics (R.J.F.), The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900
Address all correspondence and requests for reprints to: Robert J. Ferry, Jr., M.D., Director of Research and Training, Division of Pediatric Endocrinology, Department of Pediatrics, The University of Texas Health Science Center at San Antonio, 528L-2 MSC 7806, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: bob{at}uthscsa.edu.
Angiogenic factors, such as vascular endothelial-derived growth factor (VEGF) and IGF-I, play pivotal roles in endothelial proliferation and migration. IGF binding protein-3 (IGFBP-3) is emerging as a key regulator of cell growth and apoptosis, both as an IGF antagonist and as an independent molecule. We investigated the role of IGFBP-3 in VEGFmediated survival of human macrovascular umbilical vein endothelial cells (HUVEC). Specific commercial ELISAs quantified cell proliferation and apoptosis, and Akt phosphorylation was assessed by immunoblots and confocal microscopy. IGF-I and VEGF significantly stimulated HUVEC proliferation and survival. Addition of IGFBP-3 reversed both IGF- and VEGF-induced proliferation and prevented the survival induced by these factors. The antiproliferative and proapoptotic effects of exogenous IGFBP-3 upon VEGF-induced HUVEC survival were not inhibited by blockade of the type 1 IGF receptor with
IR-3 immunoglobulin, which fully prevented IGF actions. An IGFBP-3 mutant, which binds IGFs normally but has a substituted mid-region domain, lost the ability to inhibit VEGF actions. VEGF-induced phosphorylation of Akt, as evident by both specific immunoblots and confocal microscopy, was significantly and rapidly reduced in the presence of IGFBP-3, as well as wortmannin.
This work was supported in part by NIH Grants 2R01-DK-47591, 1RO1-AI-40203, 1R01-AG-20954, and 1UO1-CA-84128 (to P.C.); 5T32-DK-007688 (to S.L.F.); K08-DK-02876 and 5P30-HD-34610 (to R.F.); grants from the Juvenile Diabetes Foundation; and a Pharmacia GEM grant (to P.C.) as well as a fellowship award from Eli Lilly (to S.L.F.).
Abbreviations: DAPI, 4',6-Diamidino-2-phenylindole; EGM-2-MV Bullet Kit, Microvascular Endothelial Cell Growth Medium Bullet Kit-2; FITC, fluorescein isothiocyanate; HBD, heparin-binding domain; HUVEC, human macrovascular umbilical vein endothelial cells; IGF1R, type 1 IGF receptor; IGFBP-3, IGF binding protein-3; PI3-kinase, phosphatidylinositol 3'-kinase; SDS, sodium dodecyl sulfate; SFM, serum-free medium; VEGF, vascular endothelial-derived growth factor.
This article has been cited by other articles:
![]() |
G. Zappala, C. Elbi, J. Edwards, J. Gorenstein, M. M. Rechler, and N. Bhattacharyya Induction of Apoptosis in Human Prostate Cancer Cells by Insulin-Like Growth Factor Binding Protein-3 Does Not Require Binding to Retinoid X Receptor-{alpha} Endocrinology, April 1, 2008; 149(4): 1802 - 1812. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lofqvist, J. Chen, K. M. Connor, A. C. H. Smith, C. M. Aderman, N. Liu, J. E. Pintar, T. Ludwig, A. Hellstrom, and L. E. H. Smith From the Cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth PNAS, June 19, 2007; 104(25): 10589 - 10594. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Chang, T. Chan-Ling, E. L. McFarland, A. Afzal, H. Pan, L. C. Baxter, L. C. Shaw, S. Caballero, N. Sengupta, S. L. Calzi, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development PNAS, June 19, 2007; 104(25): 10595 - 10600. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M.E.I. Hellebrekers, V. Melotte, E. Vire, E. Langenkamp, G. Molema, F. Fuks, J. G. Herman, W. Van Criekinge, A. W. Griffioen, and M. van Engeland Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells Cancer Res., May 1, 2007; 67(9): 4138 - 4148. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Muzumdar, X. Ma, S. Fishman, X. Yang, G. Atzmon, P. Vuguin, F. H. Einstein, D. Hwang, P. Cohen, and N. Barzilai Central and Opposing Effects of IGF-I and IGF-Binding Protein-3 on Systemic Insulin Action. Diabetes, October 1, 2006; 55(10): 2788 - 2796. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Schnapp, S. Donohoe, J. Chen, D. A. Sunde, P. M. Kelly, J. Ruzinski, T. Martin, and D. R. Goodlett Mining the Acute Respiratory Distress Syndrome Proteome: Identification of the Insulin-Like Growth Factor (IGF)/IGF-Binding Protein-3 Pathway in Acute Lung Injury Am. J. Pathol., July 1, 2006; 169(1): 86 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Peters, I. Tossidou, J. Achenbach, R. Woroniecki, M. Mengel, J.-K. Park, M. Paschy, K. de Groot, H. Haller, and M. Schiffer IGF-Binding Protein-3 Modulates TGF-beta/BMP-Signaling in Glomerular Podocytes J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1644 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cohen Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology, May 1, 2006; 147(5): 2109 - 2111. [Full Text] [PDF] |
||||
![]() |
D. M.E.I. Hellebrekers, K.-W. Jair, E. Vire, S. Eguchi, N. T.H. Hoebers, M. F. Fraga, M. Esteller, F. Fuks, S. B. Baylin, M. van Engeland, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther., February 1, 2006; 5(2): 467 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al. Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Han, S. H. Oh, F. Morgillo, J. N. Myers, E. Kim, W. K. Hong, and H.-Y. Lee Hypoxia-inducible Factor 1{alpha} and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer J Natl Cancer Inst, September 7, 2005; 97(17): 1272 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-W. Lee, L. Ma, X. Yan, B. Liu, X.-k. Zhang, and P. Cohen Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXR{alpha}/Nur77 J. Biol. Chem., April 29, 2005; 280(17): 16942 - 16948. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Silha, Y. Gui, S. Mishra, A. Leckstrom, P. Cohen, and L. J. Murphy Overexpression of Gly56/Gly80/Gly81-Mutant Insulin-Like Growth Factor-Binding Protein-3 in Transgenic Mice Endocrinology, March 1, 2005; 146(3): 1523 - 1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pold, K. Krysan, A. Pold, M. Dohadwala, N. Heuze-Vourc'h, J. T. Mao, K. L. Riedl, S. Sharma, and S. M. Dubinett Cyclooxygenase-2 Modulates the Insulin-Like Growth Factor Axis in Non-Small-Cell Lung Cancer Cancer Res., September 15, 2004; 64(18): 6549 - 6555. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-W. Lee, B. Liu, L. Ma, H. Li, P. Bang, H. P. Koeffler, and P. Cohen Cellular Internalization of Insulin-like Growth Factor Binding Protein-3: DISTINCT ENDOCYTIC PATHWAYS FACILITATE RE-UPTAKE AND NUCLEAR LOCALIZATION J. Biol. Chem., January 2, 2004; 279(1): 469 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |